1 treatment center
No centers match
Try a different search term
1 SAMHSA-listed treatment center in Pasadena, California. Free, confidential help available 24/7 — most callers reach a licensed counselor in under 60 seconds.
Try a different search term
Free, confidential assistance matching you with the right program in Pasadena.
Pasadena, California has 1 SAMHSA-verified addiction treatment center offering 1 dual diagnosis, 1 outpatient. Each facility listed here is verified through the Substance Abuse and Mental Health Services Administration (SAMHSA) and provides evidence-based treatment approaches.
Outpatient programs allow Pasadena residents to receive treatment while maintaining their daily responsibilities. Sessions are typically scheduled 3-5 days per week, making it possible to continue working or attending school.
Treatment centers in Pasadena accept most major insurance plans including Medicaid, Medicare, Blue Cross Blue Shield, Aetna, Cigna, and UnitedHealthcare. Many facilities also offer sliding scale fees and payment plans. Call (319) 271-2077 to verify your coverage before admission.
Aftercare for Pasadena patients begins planning during the initial treatment episode, not at discharge. Standard components include: a named outpatient provider with a scheduled first appointment within 7 days, medication continuation plans (MAT, psychiatric medications, medical comorbidities), a sober-housing recommendation if returning home presents relapse risk, introduction to mutual-support communities matched to patient preference (AA, NA, SMART Recovery, Refuge Recovery, LifeRing), and a relapse-prevention plan with named triggers, named coping skills, and named support contacts.
Treatment programs serving Pasadena, California differ along several axes worth understanding before contact: intensity (outpatient through residential), specialty (population fit — adolescents, women-only, men-only, professionals, LGBTQ+, veterans, dual-diagnosis), modality emphasis (12-step versus secular versus evidence-based behavioral therapy versus medication-assisted treatment), and payor mix (commercial insurance, Medicaid, self-pay). Matching patient to program along these axes substantially improves engagement and outcome metrics compared to placement based on convenience or availability alone.
Detox alone — withdrawal management without subsequent treatment — produces poor outcomes across substance categories, with relapse rates approaching 80% in studies of opioid detox-only protocols. Pasadena providers typically integrate detox into a longer treatment episode: detox transitions seamlessly into residential or intensive outpatient care, with same-clinical-team continuity, rather than discharging patients post-detox without structured next-step care. This continuity is the single most impactful predictor of post-treatment success.
Pregnant women in Pasadena with active substance use should not stop opioid use abruptly if dependent — withdrawal during pregnancy carries fetal risk including preterm labor and stillbirth. Evidence-based care is buprenorphine or methadone maintenance (NOT detox), continued through pregnancy and postpartum. California maternal-fetal medicine specialists, OB-GYNs trained in addiction medicine, and SAMHSA's Center of Excellence for Pregnant and Postpartum Women with Opioid Use Disorder provide specialized care pathways for this population.
Cost expectations for Pasadena residential addiction treatment span a wide range: standard 30-day residential at facilities accepting most commercial insurance often runs $10,000-$30,000 in pre-insurance billing; premium or specialty programs (luxury, executive, specialized clinical focus) can run $30,000-$70,000+. With in-network commercial insurance, patient out-of-pocket typically lands at the plan's annual out-of-pocket maximum, often $7,000-$10,000 for an individual. Medicaid-covered treatment generally has no direct patient cost beyond modest copays where applicable.
Patients arriving at Pasadena residential facilities should expect a medical evaluation within hours of admission: vital signs, withdrawal-symptom assessment using validated scales (CIWA for alcohol, COWS for opioids), medication reconciliation with the patient's prescribing providers, and physical examination by nursing or physician staff. Medical stabilization takes priority over therapeutic programming during this early phase — patients in active withdrawal aren't expected to engage in group therapy until stabilization is achieved.
Attention-deficit/hyperactivity disorder (ADHD) in Pasadena treatment patients raises specific clinical questions: ADHD medication continuation (stimulant medications can be appropriate even in addiction-recovery contexts but require careful prescribing), evaluation of whether substance use was self-medication for untreated ADHD, and behavioral interventions for executive-function deficits that complicate early-recovery tasks like appointment-keeping, financial management, and structured-day adherence. Adult ADHD remains under-diagnosed in addiction-treatment populations.